ABVX Stock Analysis: Abivax | PA
Biotechnology | PA, France | Market Cap: 10.119m EUR | 12M Return: 1764.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.1M
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Abivax SA (ABVX) is a clinical-stage biotechnology company headquartered in Paris, France, founded in 2013. The company focuses on developing therapeutics that leverage natural immune-regulatory mechanisms to treat chronic inflammatory diseases. Its lead asset, obefazimod, is currently in Phase 3 trials for moderately to severely active ulcerative colitis (UC) and Phase 2b trials for Crohns disease. As a clinical-stage biotech with no approved products on the market, Abivax relies on equity financing and R&D milestones to fund its pipeline rather than commercial product revenue, and its prospects are closely tied to the regulatory and clinical outcomes of obefazimod in the competitive inflammatory bowel disease (IBD) therapeutic space.
- Obefazimod Phase 3 ulcerative colitis results expected
- Cash burn accelerates ahead of obefazimod approval filing
- Competition intensifies from JAK and S1P UC therapies
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.52 > 0.02 and ΔFCF/TA 82.96 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -259.7m > Net Income -537.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (79.3m) vs 12m ago 25.03% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 6.46%; Δ -6.46% > 0%) |
| Interest Coverage Ratio: -10.99 > 6 (EBIT TTM -387.6m / Interest Expense TTM 35.3m) |
| A: 0.82 (Total Current Assets 513.2m - Total Current Liabilities 62.2m) / Total Assets 547.1m |
| B: -1.40 (Retained Earnings -764.3m / Total Assets 547.1m) |
| C: -1.09 (EBIT TTM -387.6m / Avg Total Assets 357.0m) |
| D: 3.65 (Book Value of Equity 429.6m / Total Liabilities 117.5m) |
| Altman-Z'' = -2.60 = D |
As of July 08, 2026, the stock is trading at EUR 126.80 with a total of 179,254 shares traded. Over the past week, the price has changed by +9.78%, over one month by +42.23%, over three months by +27.37% and over the past year by +1764.71%.
Current recommended Stop Loss: 106.40 (which is 16.1% or 2.2 ATR below the current price).
Abivax has no consensus analysts rating.
P/E Forward = 1.0044
P/S = 2056.6516
P/B = 25.0774
Revenue TTM = 0.0 EUR
EBIT TTM = -387.6m EUR
EBITDA TTM = -386.4m EUR
Long Term Debt = unknown (none)
Short Term Debt = 1.30m EUR (from shortTermDebt, last fiscal year)
Debt = 33.5m EUR (from shortLongTermDebtTotal, last fiscal year) + Leases 1.45m
Net Debt = -443.9m EUR (calculated: Debt 33.5m - CCE 477.4m)
Enterprise Value = 9.67b EUR (10.1b + Debt 33.5m - CCE 477.4m)
Interest Coverage Ratio = -10.99 (Ebit TTM -387.6m / Interest Expense TTM 35.3m)
EV/FCF = -34.06x (Enterprise Value 9.67b / FCF TTM -284.1m)
FCF Yield = -2.94% (FCF TTM -284.1m / Enterprise Value 9.67b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.07m) / Revenue TTM)
Tobins Q-Ratio = 17.68 (Enterprise Value 9.67b / Total Assets 547.1m)
Interest Expense / Debt = 105.1% (Interest Expense 35.3m / Debt 33.5m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -290.7m (EBIT -387.6m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 8.25 (Total Current Assets 513.2m / Total Current Liabilities 62.2m)
Debt / Equity = 0.08 (Debt 33.5m / totalStockholderEquity, last quarter 429.6m)
Debt / EBITDA = 1.15 (negative EBITDA) (Net Debt -443.9m / EBITDA -386.4m)
Debt / FCF = 1.56 (negative FCF - burning cash) (Net Debt -443.9m / FCF TTM -284.1m)
Total Stockholder Equity = 336.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -150.7% (out of range, set to none)
RoE = -159.7% (Net Income TTM -537.9m / Total Stockholder Equity 336.9m)
RoCE = -79.93% (EBIT -387.6m / Capital Employed (Total Assets 547.1m - Current Liab 62.2m))
RoIC = -59.78% (negative operating profit) (NOPAT -290.7m / Invested Capital 486.2m)
WACC = 16.48% (E(10.1b)/V(10.2b) * Re(16.53%) + (debt cost/tax rate unavailable))
Discount Rate = 16.53% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 78.88%
[DCF] Fair Price = unknown (Cash Flow -284.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.35 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.03 | Chg30d=+0.00% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.82 | Chg30d=-1.86% | Revisions=+40% | Analysts=2
EPS current Year (2026-12-31): EPS=-3.68 | Chg30d=-8.53% | Revisions=-12% | GrowthEPS=+23.8% | GrowthRev=+1528.8%
EPS next Year (2027-12-31): EPS=-3.05 | Chg30d=+2.69% | Revisions=+17% | GrowthEPS=+17.1% | GrowthRev=+17.8%
[Analyst] Revisions Ratio: +13% (up=7, down=5)